![Inside Honeywell’s plan for a new F-35 cooling system [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/07/8509355-1-scaled-e1721820217290.jpg?#)
FDA aims for 'rapid or instant' drug reviews, with AI tool initially assessing applications
The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently demonstrated by the coronation of new generative AI tool Elsa. Now, Makary and Vinay Prasad, M.D., director of the FDA’s Center for Biologics Evaluation and Research, have published an outline of the FDA’s priorities that includes dramatically hastened drug reviews powered by AI document evaluation.
The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently demonstrated by the coronation of new generative AI tool Elsa. Now, Makary and Vinay Prasad, M.D., director of the FDA’s Center for Biologics Evaluation and Research, have published an outline of the FDA’s priorities that includes dramatically hastened drug reviews powered by AI document evaluation.
